ARCHIVED Skip navigation.PDF Version     To Publications Page     To Home Page


Appalachia High Intensity Drug Trafficking Area Drug Market Analysis 2010

Publication Date: May 2010

Document ID: 2010-R0813-001Cover image of Appalachia HIDTA Drug Market Analysis 2010.

Archived on: September 1, 2011. This document may contain dated information. It remains available to provide access to historical materials.

This assessment is an outgrowth of a partnership between the NDIC and HIDTA Program for preparation of annual assessments depicting drug trafficking trends and developments in HIDTA Program areas. The report has been coordinated with the HIDTA, is limited in scope to HIDTA jurisdictional boundaries, and draws upon a wide variety of sources within those boundaries.

Your questions, comments, and suggestions for future subjects are welcome at any time. Addresses are provided at the end of the page.


Strategic Drug Threat Developments

HIDTA Overview

Drug Threat Overview

Drug Trafficking Organizations




Drug-Related Crime


Illicit Finance


Appendix A. Table



List of Figures

Figure 1. Appalachia High Intensity Drug Trafficking Area

List of Tables

Table 1. Appalachia HIDTA Initiative Seizures, by Drug, in Kilograms, 2009
Table 2. Methamphetamine Laboratories Seized in Appalachia HIDTA Counties, 2005-2009
Table 3. Cannabis Plants Eradicated at Outdoor and Indoor Grow Sites in Appalachia HIDTA Counties, 2005-2009

List of Tables in Appendix A

Table A1. Drug-Related Treatment Admissions to Publicly Funded Facilities in Kentucky, Tennessee, and West Virginia, by Drug, 2004-2008

Strategic Drug Threat Developments

The principal drug threats to the Appalachia High Intensity Drug Trafficking Area (HIDTA) region are the diversion and abuse of controlled prescription drugs (CPDs), particularly prescription opioid pain relievers,a the distribution and abuse of cocaine, and the production and abuse of methamphetamine. In addition, marijuana production and distribution continue to pose serious threats to the region.

The following are significant strategic drug threat developments in the Appalachia HIDTA region:

To Top      To Contents


National Drug Intelligence Center
319 Washington Street, 5th Floor
Johnstown, PA 15901-1622

Tel. (814) 532-4601
FAX (814) 532-4690
E-mail NDIC.Contacts@usdoj.gov


Office of Policy and Interagency Affairs
U.S. Department of Justice
Robert F. Kennedy Building, Room 3341
950 Pennsylvania Avenue, NW
Washington, D.C. 20530-2000

Telephone: (202) 532-4040
FAX (202) 514-4252

Web Addresses

ADNET:  http://ndicosa.adnet.sgov.gov
DOJ:  http://www.justice.gov/archive/ndic/
LEO:  https://www.leo.gov/http/leowcs.leopriv.gov/lesig/archive/ndic/index.htm
RISS:  ndic.riss.net


a. Opioid pain relievers include codeine, fentanyl (Duragesic, Actiq), hydromorphone (Dilaudid), meperidine (Demerol), morphine (MS Contin), oxycodone (OxyContin), methadone (Dolophine), and hydrocodone combinations (Vicodin, Lortab, and Lorcet).
b. Pseudoephedrine smurfing is a method used by some methamphetamine producers to acquire large quantities of pseudoephedrine by enlisting the assistance of several friends or associates in making purchases at or below the legal thresholds from multiple retail locations.

To Top     To Contents     To Next Page

To Publications Page     To Home Page


End of page.